Paper Review Records
全部论文审稿周期
5 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
103
天
Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates
作者
Wentao Shang; Hua Shang; Josie Cai; Qin Vicky; Lyan Chen; Huiqiang Wang; Xiaobo Zhang展开收起
作者单位
1. Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China; 2. Shanghai Biophy Biological Pharmaceutical Co, Ltd, Shanghai, China展开收起
298
天
Integrated Analysis of Single-cell and Bulk RNA-Sequencing Identifies a Signature Based on Cancer-related Fibroblast Marker Genes to Predict Prognosis and Therapy Response in Lung Adenocarcinoma
作者
Gengqiu Liu; Jiacheng Feng; Yufeng Huang; Junhang Zhang; Yong Li展开收起
作者单位
1. Department of Thoracic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China; 2. The Pharmacy College of Jiangxi Science and Technology Normal University. Jiangxi, Nanchang, China; 3. Department of Thoracic Surgery, BaoAn Central Hospital of Shenzhen, Shenzhen, China展开收起
121
天
Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics
作者
Hélène Vanacker; Robert Connacher; Alexandra Meurgey; Julien Bollard; Valéry Attignon; Franck Tirode; Myriam Jean-Denis; Mehdi Brahmi; Jean-Yves Blay; Ruoxi Wang; Dennis Williams; Armelle Dufresne展开收起
作者单位
1. Centre Léon-Bérard, Lyon, France; 2. Adaptimmune, Philadelphia, PA; 3. Adaptimmune, Abingdon, Oxfordshire, UK展开收起
185
天
Mucin-1–Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host
作者
Ru Zhou; Shu-ta Wu; Mahboubeh Yazdanifar; Chandra Williams; Alexa Sanders; Cory Brouwer; John Maher; Pinku Mukherjee展开收起
作者单位
1. Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC; 2. Medpace, Irving, TX; 3. Adaptive Biotechnologies, South San Francisco, CA; 4. Pfizer, Cambridge, MA; 5. Department of Bioinformatics, University of North Carolina at Charlotte, Charlotte, NC; 6. King’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Cancer Centre, London, UK展开收起
77
天
Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non–Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET, or RET Alterations: A Systematic Literature Review
作者
Katherine G. Akers; Sabine Oskar; Bin Zhao; Andrew M. Frederickson; Ashwini Arunachalam展开收起
作者单位
1. PRECISIONheor, New York, NY; 2. Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天